Head & Neck – Open Studies
| cta_upcoming | s_external_protocol_id | Study Details | Site | Indication | Indication | Therapeutic Area | Sub Therapeutic Area2 | Sub Therapeutic Area | Molecular Targets | Molecular Target | s_recruitment_criteria | Sponsor | Phase | Team | Open to Accrual | Open to Accrual Date | Close to Accrual Date (String) | Completely Closed Date (String) | Site Initiation Visit Date (String) | Inclusion and Exclusion Criteria 2 | Notes | PI | Study Coordinator | s_nick | s_other_id | Inclusion and Exclusion Criteria | Email CTA | Site Target | cta_enrolment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antengene - ATG-017-001 - ERASER - CT1253 | ERASER A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumours and Hematological Malignancies ATG-017-001 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumours and Hematological Malignancies | Antengene (AUS) PTY. LTD | Phase I | ACT 1 | Yes | 12/05/2020 | 13/08/2020 | Mark Voskoboynik | Nicola Byrne | ERASER | ATG-017-001 | Click here | Report a correction | 10 | 5 | |||||||||
| Anwita Biosciences - AWT020-001 - CT1698 | AWT020001 A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer AWT020-001 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-human, Open-label Study of Single-agent AWT020 in Patients with Progressive Locally Advanced or Metastatic Cancer | Anwita Biosciences Australia Pty Ltd | Phase I/II | Yes | 9/11/2023 | Mark Voskoboynik | AWT020001 | AWT020-001 | Click here | Report a correction | 8 | 0 | ||||||||||||
| Aulos Bioscience, Inc - CP-AU-007-01 CT1542 | CT1542 A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer CP-AU-007-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer | PPD | Phase I/II | ACT 1 | Yes | 5/11/2022 | 27/10/2022 | PHASE 1 TRIAL METASTATIC/Advanced patients | Andrew Haydon | CT1542 | CP-AU-007-01 | Click here | Report a correction | 5 | 8 | |||||||||
| Covance - ATG-101-001 - PROBE - CT1471 | PROBE A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101-001 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | Antengene (AUS) PTY. LTD | Phase I | ACT 1 | Yes | 30/03/2022 | 23/03/2022 | Mark Voskoboynik | PROBE | ATG-101-001 | Click here | Report a correction | 8 | 4 | ||||||||||
| Gilead - GS-US-548-5916 - ELEVATE HNSCC - CT1537 | ELEVATE HNSCC A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma GS-US-548-5916 | Alfred - Medical Oncology | Neo-adjuvant | 1st Line, Adjuvant, Neo-adjuvant | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma | Gilead | Phase II | ACT 3 | Yes | 21/09/2022 | 13/10/2022 | Miles Andrews | ELEVATE HNSCC | GS-US-548-5916 | Click here | Report a correction | 3 | 1 | ||||||||
| Iksuda Therapeutics - IKS14-01 - IKS01401 - CT1705 | IKS14-01 A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors IKS01401 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors | Medpace Australia | Phase I | Yes | 1/12/2023 | 23/11/2023 | Malaka Ameratunga | IKS14-01 | IKS01401 | Click here | Report a correction | 5 | 0 | |||||||||||
| IQVIA - LM302-01-201 - LANOVA - CT1476 | LANOVA A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors LM302-01-201 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors | IQVIA | Phase I/II | ACT 1 | Yes | 22/04/2022 | 21/04/2022 | Ben Markman | LANOVA | LM302-01-201 | Click here | Report a correction | 3 | 7 | ||||||||||
| Maverick Therapeutics - CP-MVC-101-01 - CT1632 | COBRA A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer CP-MVC-101-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer | PPD | Phase I/II | Yes | 15/06/2023 | 25/05/2023 | Andrew Haydon | COBRA | CP-MVC-101-01 | Click here | Report a correction | 5 | 1 | |||||||||||
| MSD - MK-3475-630 - KEYNOTE-630 - CT1137 | KEYNOTE-630 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) MK-3475-630 | Alfred - Medical Oncology | Adjuvant | Adjuvant | Head & Neck | Cutaneous SCC | Cutaneous SCC | PD-1 | PD-1 | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) | Merck Serono | Phase III | ACT 2 | Yes | 23/08/2019 | 7/08/2019 | Anti-PD-1 immunotherapy Adjuvant therapy for locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy | Mitchell Chipman | Jane Berry | KEYNOTE-630 | MK-3475-630 | Click here | Report a correction | 5 | 11 | ||||
| MSD - MK4280A-010 - 010-00 - CT | MK4280A-010 A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors 010-00 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors | Merck Sharp & Dohme (MSD) | Phase II | Yes | 30/11/2023 | 16/11/2023 | Mark Voskoboynik | MK4280A-010 | 010-00 | Click here | Report a correction | 4 | 1 | |||||||||||
| Multitude - AMT-116-01 - CT1634 | AMT-116-01 First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT11601 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors | Multitude Therapeutics | Phase I | Yes | 16/11/2023 | Mark Voskoboynik | AMT-116-01 | AMT11601 | Click here | Report a correction | 5 | 0 | ||||||||||||
| Roche - GO42144 - CT1252 | A PHASE I DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION GO42144 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A PHASE I DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION | Roche | Phase I | ACT 1 | Yes | 5/05/2021 | 3/05/2021 | Ben Markman | Shelley Firth | GO42144 | Click here | Report a correction | 5 | 5 | ||||||||||
| 21/125 - NORTH - CP-MGA271-06 - CT1350 | A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Barwon | Head & Neck | A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination with Retifanlimab or Tebotelimab in the First-Line Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Novotech | Phase II | Medical Oncology | No | 8/11/2021 | 7/07/2022 | 28/10/2021 | Madhu Singh | Report a correction | 2 | 0 | ||||||||||||||
| Beigene - BGB-900-105 (AdvanTIG-105) - CT1468 | BGB-900-105 Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors BGB-900-105 | Bendigo | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/1b Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors | Phase Ib | Yes | 7/03/2022 | 28/02/2022 | Sam Harris | BGB-900-105 | BGB-900-105 | Click here | Report a correction | 2 | 2 | ||||||||||||
| R2810-ONC-1788 - cPOST - CT1126 | cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788 | Bendigo | Neo-adjuvant | Adjuvant, Neo-adjuvant | Head & Neck | Cutaneous SCC | Cutaneous SCC | PD-1 | PD-1 | A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. | Regeneron Pharmaceuticals | Phase III | Yes | 3/09/2020 | 24/06/2020 | Anti-PD-1 monoclonal antibody. Amendment underway to broaden the inclusion criteria. Recruitment slow. | Sam Harris | cPOST | R2810-ONC-1788 | Click here | Report a correction | 4 | 5 | ||||||
| BMS - CA052002 - CT1620 | A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors CA052002 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors | Bristol Myers Squibb | Phase I/II | Yes | 14/08/2023 | 14/08/2023 | Anis Hamid | A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors | CA052002 | Click here | Report a correction | 12 | 1 | |||||||||||
| DynamiCure Biotechnology - DCSZ11-101 - CT1636 | A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors DCSZ11-101 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors | Novotech | Phase I | Yes | 2/11/2023 | Gary Richardson | DCSZ11-101 | Click here | Report a correction | 6 | 0 | |||||||||||||
| Multitude Therapeutics - AMT-116-01 - CT1634 | AMT-116-01 First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT11601 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors | Multitude Therapeutics | Phase I | Yes | 22/09/2023 | 20/09/2023 | AMT-116-01 | AMT11601 | Click here | Report a correction | 6 | 0 | ||||||||||||
| Novotech - MHB036C-CP001EN - CT1561 | MHB036C Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors MHB036C-CP001EN | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors | Novotech | Phase I/II | Yes | 9/03/2023 | Gary Richardson | MHB036C | MHB036C-CP001EN | Click here | Report a correction | 5 | 0 | ||||||||||||
| Novotech - MHB088C-CP001EN - CT1570 | MHB088C Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors MHB088C-CP001EN | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors | Novotech | Phase I/II | Yes | 9/03/2023 | Gary Richardson | MHB088C | MHB088C-CP001EN | Click here | Report a correction | 5 | 0 | ||||||||||||
| Nuvation Bio - NUV-868-01 - CT1586 | Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868-01 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Novotech | Phase I/II | Yes | 21/08/2023 | 8/08/2023 | Shehara Mendis | Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | NUV-868-01 | Click here | Report a correction | 6 | 1 | |||||||||||
| PharmAbcine - MarkV-01 - KEYNOTE-E80 - CT1657 | MarkV-01 A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors MarkV-01 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors | Novotech | Phase I | Yes | 20/11/2023 | Shehara Mendis | MarkV-01 | MarkV-01 | Click here | Report a correction | 12 | 0 | ||||||||||||
| RemeGen Co. - RC198-G001 - CT1604 | CT1604 A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors RC198-G001 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, First-in-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors | Novotech | Phase I | Yes | 9/08/2023 | 26/07/2023 | Gary Richardson | CT1604 | RC198-G001 | Click here | Report a correction | 5 | 1 | |||||||||||
| Servier - CL1-95012-001 - CT1463 | CT1463 A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS CL1-95012-001 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS | Servier laboratories (AUST.) | Phase I/II | Yes | 3/06/2022 | 26/05/2022 | Gary Richardson | CT1463 | CL1-95012-001 | Click here | Report a correction | 5 | 1 | |||||||||||
| Surface Oncology - SRF617-101 - KEYNOTE-A62 - CT1466 | KEYNOTE-A62 A Phase I Study of SRF617 in Patients with Advanced Solid Tumours SRF617-101 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A Phase I Study of SRF617 in Patients with Advanced Solid Tumours | Clinipace | Phase I | Yes | 22/06/2022 | 22/06/2022 | Gary Richardson | KEYNOTE-A62 | SRF617-101 | Click here | Report a correction | 5 | 1 | |||||||||||
| Tigermed - AMT-253-01 - AMT253-01 - CT1679 | AMT253-01 First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT-253-01 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors | Multitude Therapeutics | Phase I | Yes | 3/11/2023 | 2/11/2023 | Gary Richardson | AMT253-01 | AMT-253-01 | Click here | Report a correction | 5 | 0 | |||||||||||
| Antido Therapeutics - AT-0174-001 - CT1692 | Antido A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies AT-0174-001 | Grampians Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacology, and Preliminary Efficacy of AT-0174 in Subjects with Advanced Solid Malignancies | Antido Therapeutics (Australia) Pty Ltd | Phase I | Yes | 19/10/2023 | Lizzie Lim | Antido | AT-0174-001 | Report a correction | 3 | 0 | |||||||||||||
| George Clinical - CIBI334A101 - INNOVENT - CT1644 | INNOVENT A Phase 1 Study of IBI334 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors CIBI334A101 | Grampians Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Study of IBI334 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors | The George Institute | Phase I | Yes | 17/07/2023 | 5/07/2023 | Lizzie Lim | INNOVENT | CIBI334A101 | Click here | Report a correction | 12 | 0 | |||||||||||
| PharmAbcine - MArkV-01 - KEYNOTE-E80 - CT1657 | KEYNOTE-E80 A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors MarkV-01 | Grampians Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors | Novotech | Phase Ib | Yes | 6/11/2023 | Lizzie Lim | KEYNOTE-E80 | MarkV-01 | Click here | Report a correction | 3 | 0 | ||||||||||||
| PharmaSols - MT-5111_001 - CT1464 | 5111_001 A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors MT - 5111_001 | GVH | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors | Molecular Templates Inc | Phase I | Yes | 11/02/2022 | 11/02/2022 | Stage: Metastatic Breast Cancer Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort | Arvind Sahu | 5111_001 | MT - 5111_001 | Click here | Report a correction | 4 | 0 | ||||||||||
| PMCC Sponsored - Cancer Statewide_26072023 - NC | Cancer Statewide A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia Cancer Statewide_26072023 | GVH | Head & Neck | Other | Other | A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia | PMCC Sponsored | Phase III | Yes | 14/09/2023 | Arvind Sahu | Cancer Statewide | Cancer Statewide_26072023 | Report a correction | 35 | 0 | |||||||||||||
| 13/23 TROG - 12.01 - HPV OROPHARYNX - NC57 | A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX) | PCCTU | Head & Neck | A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV OROPHARYNX) | Trans Tasman Radiation Oncology Group - TROG | Phase III | PCCTU MoncC | No | 1/04/2013 | 13/09/2018 | 10/05/2013 | Danny Rischin | Report a correction | 40 | 56 | ||||||||||||||
| 15/82 Merck - MK3475-048 - CT755 | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. MK3475-048 | PCCTU | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | Merck Serono | Phase III | PCCTU MoncC | No | 28/05/2015 | 3/05/2017 | 7/07/2015 | Danny Rischin | MK3475-048 | Report a correction | 8 | 14 | |||||||||||
| 16/38 GlaxoSmithKline - 204691 - ICOS - CT824 | A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors | PCCTU | Head & Neck | A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors | Glaxo Smith Kline - GSK | Phase I | PCCTU MoncC | No | 1/07/2016 | 30/06/2019 | 30/08/2016 | Danny Rischin | Report a correction | 7 | 32 | ||||||||||||||
| 16/41 Regeneron Pharmaceuticals Inc - R2810-ONC-1540 - Regeneron 2 - CT823 | A phase 2 study of REGN2810, a fully human monoclonal antibody to programmed death -1 (PD-1), in patients with advanced cutaneous squamous cell carcinoma R2810-ONC-1540 | PCCTU | Head & Neck | Cutaneous SCC | Cutaneous SCC | A phase 2 study of REGN2810, a fully human monoclonal antibody to programmed death -1 (PD-1), in patients with advanced cutaneous squamous cell carcinoma | PPD | Phase II | PCCTU MoncC | No | 1/07/2016 | 31/01/2017 | 12/08/2016 | Danny Rischin | R2810-ONC-1540 | Report a correction | 5 | 58 | |||||||||||
| 17/09 BMS - CA209-651 - CT867 | An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | PCCTU | Head & Neck | An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Bristol Myers Squibb - BMS | Phase III | PCCTU MoncC | No | 1/06/2016 | 31/03/2016 | 16/02/2017 | Danny Rischin | Report a correction | 4 | 10 | ||||||||||||||
| 17/13 Merck - MK3475-412 - CT902 | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenanace therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412) MK3475-412 | PCCTU | Head & Neck | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenanace therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412) | Merck Serono | Phase III | PCCTU MoncC | No | 23/06/2017 | 1/03/2021 | 21/07/2017 | Danny Rischin | MK3475-412 | Report a correction | 6 | 7 | |||||||||||||
| 17/210 Roche - WO40242 - IMvoke10 - CT972 | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti Pd-L1 Antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced Squamous Cell Carcinoma of the head and neck (WO40242) | PCCTU | Head & Neck | A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti Pd-L1 Antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced Squamous Cell Carcinoma of the head and neck (WO40242) | Roche | Phase III | PCCTU MoncC | No | 27/02/2018 | 31/05/2021 | 27/02/2018 | Danny Rischin | Report a correction | 3 | 1 | ||||||||||||||
| 19/127 Loxo Oncology - LOXO-RET-18037 - LIBRETTO-201 - CT1150 | LIBRETTO-201 A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation LOXO-RET-18037 | PCCTU | Head & Neck | Thyroid | Thyroid | A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation | Southern Star Research | N/A | PCCTU MoncC | Yes | 1/12/2019 | 3/02/2020 | This study is for any patient with a RET activated cancer who is ineligible for the other available RET targeted trials. It has fixed limits to enrolment per site over specified time periods. Open for accrual. | Ben Solomon | LIBRETTO-201 | LOXO-RET-18037 | Report a correction | 5 | 10 | ||||||||||
| 19/187 Eli Lilly - J2G-MC-JZJB - LIBRETTO-531 - CT1176 | LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | PCCTU | Head & Neck | Thyroid | Thyroid | A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer | Eli Lilly | Phase III | PCCTU MoncC | Yes | 1/04/2020 | 30/04/2020 | TK inhibitor. Worldwide shorage of Vandertanib. | Annette Lim | LIBRETTO-531 | J2G-MC-JZJB | Click here | Report a correction | 6 | 1 | |||||||||
| 19/217 Syneos - BGB-3245-AU-001 - MapKure - CT1152 | MapKure A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors BGB-3245-AU-001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A First-in-Human, Phase 1a/1b, Open-Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients with Advanced or Refractory Tumors | Syneos | Phase Ib | PCCTU EDD | Yes | 28/02/2020 | 16/03/2020 | Jayesh Desai | EDD PMC | MapKure | BGB-3245-AU-001 | Click here | Report a correction | 12 | 12 | |||||||||
| 19/233 GSK - 209229 - INDUCE 3 - CT1170 | A Randomized, Double-blind, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | PCCTU | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized, Double-blind, Adaptive, Phase II/III Study of Pembrolizumab with or without GSK3359609 for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Glaxo Smith Kline - GSK | Phase II/III | PCCTU MoncC | No | 1/12/2019 | 1/05/2021 | 3/12/2019 | Danny Rischin | Click here | Report a correction | 8 | 5 | |||||||||||
| 19/235 Regeneron Pharmaceuticals - R2810-ONC-1901 - CT1180 | A phase 2 study of neoadjuvant cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | PCCTU | Head & Neck | A phase 2 study of neoadjuvant cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC) | ICON Clinical Research | Phase II/III | PCCTU MoncC | No | 31/01/2020 | 1/09/2021 | 14/04/2020 | Danny Rischin | Report a correction | 5 | 11 | ||||||||||||||
| 19/25 Kura Oncology - KO-TIP-007 - CT1111 | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) | PCCTU | Head & Neck | The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) | PRA International | N/A | PCCTU MoncC | No | 12/08/2019 | 11/05/2022 | 26/07/2019 | Danny Rischin | Report a correction | 3 | 0 | ||||||||||||||
| 19/68 Regeneron Pharmaceuticals Inc - R3767-ONC-1613 - CT1116 | A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies | PCCTU | Head & Neck | A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies | ICON Clinical Research | Phase I | PCCTU MoncC | No | 10/10/2019 | 22/03/2022 | 30/10/2019 | Danny Rischin | Report a correction | 8 | 4 | ||||||||||||||
| 19/87 Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 | cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788 | PCCTU | Neo-adjuvant | Adjuvant, Neo-adjuvant | Head & Neck | Cutaneous SCC | Cutaneous SCC | PD-1 | PD-1 | A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. | ICON Clinical Research | Phase III | PCCTU MoncC | Yes | 1/08/2019 | 3/09/2019 | Anti-PD-1 monoclonal antibody. Amendment underway to broaden the inclusion criteria. Recruitment slow. | Danny Rischin | cPOST | R2810-ONC-1788 | Click here | Report a correction | 20 | 20 | |||||
| 20/01 Decibel Therapeutics - DB-020-002 - CT1183 | Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin | PCCTU | Head & Neck | Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin | Syneos | Phase I | PCCTU MoncC | No | 15/12/2019 | 24/11/2022 | 3/02/2020 | Danny Rischin | Report a correction | 4 | 7 | ||||||||||||||
| 20/044 - IMPARP-HRD - VC007 | IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects 20/044, VC007 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects | Peter MacCallum Cancer Centre | Phase II | PCCTU EDD | Yes | 20/01/2022 | 20/01/2022 | Stephen Luen | EDD PMC | IMPARP-HRD | 20/044, VC007 | Click here | Report a correction | 10 | 17 | |||||||||
| 20/143 Antengene - ATG-017-001 - ERASER - CT1253 | ERASER A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumors and Hematological Malignancies ATG-017-001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy with Nivolumab in Patients with Advanced Solid Tumors and Hematological Malignancies | Labcorp Development Pty Ltd | Phase I | PCCTU EDD | Yes | 1/07/2020 | 13/08/2020 | Ben Tran | EDD PMC | ERASER | ATG-017-001 | Click here | Report a correction | 20 | 5 | |||||||||
| 20/146 Roche - GO42144 - CT1252 | A PHASE I DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION GO42144 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A PHASE I DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION | Roche | Phase I | PCCTU EDD | Yes | 10/09/2020 | 27/08/2020 | Jayesh Desai | EDD PMC | GO42144 | Click here | Report a correction | 15 | 18 | ||||||||||
| 20/152 GSK - 209227 - INDUCE-4 - CT1255 | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | PCCTU | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination with Pembrolizumab and 5FU-Platinum Chemotherapy versus Placebo in Combination with Pembrolizumab plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Glaxo Smith Kline - GSK | Phase II/III | PCCTU MoncC | No | 31/07/2020 | 1/05/2021 | 10/09/2020 | Annette Lim | Click here | Report a correction | 5 | 6 | |||||||||||
| 20/214 AstraZeneca - D7310C00001 - Interlink-1 - CT1284 | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor | PCCTU | Head & Neck | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor | AstraZeneca | Phase III | PCCTU MoncC | No | 18/09/2020 | 1/08/2022 | 27/10/2021 | Danny Rischin | PCCTU MoncC Team | Report a correction | 10 | 11 | |||||||||||||
| 20/236 Debiopharm - 1143-SCCHN-301 - CT1298 | A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). | PCCTU | Head & Neck | A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). | Syneos | Phase III | PCCTU MoncC | No | 15/11/2020 | 25/02/2022 | 23/11/2020 | Annette Lim | Report a correction | 5 | 0 | ||||||||||||||
| 2014.009 Exelixis - XL184-401 - CT720 | A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients. | PCCTU | Head & Neck | A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients. | PPD | Phase III | PCCTU MoncC | No | 1/04/2015 | 28/02/2018 | 1/05/2015 | Jeanne Tie | Report a correction | 1 | 4 | ||||||||||||||
| 21/166 - AstraZeneca - D6900C00001 - B7H4 - Astra Solid - CT1427 (EDD - Primary) | A Phase I/IIa Multi-center, Open-label, Modular Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 as Monotherapy and in Combination with Anticancer Agents, in Participants with Advanced or Metastatic Solid Malignancies D6900C00001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase I/IIa Multi-center, Open-label, Modular Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 as Monotherapy and in Combination with Anticancer Agents, in Participants with Advanced or Metastatic Solid Malignancies | AstraZeneca | Phase I/IIa | PCCTU EDD | Yes | 23/11/2021 | 15/11/2021 | Linda Mileshkin | EDD PMC | D6900C00001 | Click here | Report a correction | 10 | 12 | ||||||||||
| 21/168 ALX Oncology - AT148003 - ASPEN-03 - CT1423 | ASPEN-03 A Phase 2 Study of ALX148 in combination with Pembrolizumab in Patients with Advanced head and neck Squamous Cell Carcinoma (Aspen-03) AT148003 | PCCTU | 1st Line | 1st Line | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 2 Study of ALX148 in combination with Pembrolizumab in Patients with Advanced head and neck Squamous Cell Carcinoma (Aspen-03) | IQVIA | Phase II | PCCTU MoncC | Yes | 19/10/2021 | 26/10/2021 | accruing well | Danny Rischin | ASPEN-03 | AT148003 | Click here | Report a correction | 5 | 4 | |||||||
| 21/172 ALX Oncology - AT148004 - ASPEN-04 - CT1424 | ASPEN-03 A Phase 2 Study of ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma AT148004 | PCCTU | 1st Line | 1st Line | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 2 Study of ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma | IQVIA | Phase II | PCCTU MoncC | Yes | 19/10/2021 | 26/10/2021 | accruing well | Annette Lim | ASPEN-03 | AT148004 | Click here | Report a correction | 5 | 11 | |||||||
| 21/46 Erasca - ERAS-601-01 - FLAGSHP-1 - CT1358 (Monc B - Secondary) | FLAGSHP-1 An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1) ERAS-601-01 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1) | IQVIA | Phase Ib | PCCTU MoncB | Yes | 28/06/2021 | 15/07/2021 | Danny Rischin | FLAGSHP-1 | ERAS-601-01 | Click here | Report a correction | 8 | 1 | ||||||||||
| 21/46 Erasca - ERAS-601-01 - FLAGSHP-1 - CT1358 (Monc C - Primary) | FLAGSHP-1 An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1) ERAS-601-01 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS601 SHP2 Inhibitor as a Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced or Metastatic Solid Tumors (FLAGSHP-1) | IQVIA | Phase Ib | PCCTU MoncC | Yes | 28/06/2021 | 15/07/2021 | Danny Rischin | FLAGSHP-1 | ERAS-601-01 | Click here | Report a correction | 8 | 1 | ||||||||||
| 22/128 - Axelia Oncology Pty Ltd. - AXA-042-FIH-01 - CT1478 | A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors. AXA-042-FIH-01 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors. | Axelia Oncology Pty Ltd | Phase I | PCCTU EDD | Yes | 10/02/2023 | 6/09/2022 | Ben Tran | AXA-042-FIH-01 | Report a correction | 15 | 2 | ||||||||||||
| 22/158 - Pfizer - C3651003 - PROACC-1 - CT1534 | PROACC-1 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab In Patients with Cancer, Cachexia, and Elevated Concentrations of Gdf-15, Followed by an Optional Open-Label Treatment Period C3651003 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab In Patients with Cancer, Cachexia, and Elevated Concentrations of Gdf-15, Followed by an Optional Open-Label Treatment Period | Pfizer Australia Pty Ltd | Phase II | PCCTU MoncB | Yes | 9/03/2023 | 9/03/2023 | Brian Le | PROACC-1 | C3651003 | Click here | Report a correction | 5 | 1 | ||||||||||
| 22/205 - AstraZeneca - D9350C00001 - AZD9592 - EGRET - CT1560 | AZD9592 EGRET A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors D9350C00001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors | AstraZeneca | Phase I | PCCTU EDD | Yes | 19/01/2023 | 12/01/2023 | Ben Solomon | AZD9592 EGRET | D9350C00001 | Click here | Report a correction | 8 | 4 | ||||||||||
| 22/216 - SpringWorks Therapeutics, Inc - MEKRAF-AST-101 - CT1569 | A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients with Advanced Solid Tumors MEKRAF-AST-101 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2a Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Mirdametinib in Combination With BGB-3245 in Patients with Advanced Solid Tumors | ADVANCED CLINICAL PTY LTD | Phase I/IIa | PCCTU EDD | Yes | 6/04/2023 | 4/04/2023 | Jayesh Desai | MEKRAF-AST-101 | Click here | Report a correction | 8 | 2 | |||||||||||
| 22/30 - ONJ2021-006 I-FIRST NC292 | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients with RAIR Thyroid Cancer (I-FIRST study) | PCCTU | Head & Neck | Thyroid | Thyroid | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients with RAIR Thyroid Cancer (I-FIRST study) | ONJ Cancer Research Institute | Phase II | PCCTU MoncC | Yes | 1/03/2022 | 1/03/2022 | Annette Lim | Report a correction | 2 | 2 | |||||||||||||
| 22/34 Antengene - ATG-101-001 (PROBE) - CT1471 | PROBE A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101-001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | Phase I | PCCTU EDD | Yes | 3/03/2022 | 30/03/2022 | Annette Lim | PROBE | ATG-101-001 | Click here | Report a correction | 10 | 1 | |||||||||||
| 23/123 - IO Biotech - IO102-IO 103-032 - IOB?032/PN?E40 - CT1694 | IOB?032/PN?E40 Phase II, multi?cohort trial of neoadjuvant and post?surgery IO102?IO103 and pembrolizumab in patients with selected resectable tumors IO102-IO 103-032 | PCCTU | Head & Neck | Cutaneous SCC | Cutaneous SCC | Phase II, multi?cohort trial of neoadjuvant and post?surgery IO102?IO103 and pembrolizumab in patients with selected resectable tumors | Accelagen | Phase II | PCCTU MoncC | Yes | 31/10/2023 | 12/10/2023 | Annette Lim | PCCTU MoncC Team | IOB?032/PN?E40 | IO102-IO 103-032 | Click here | Report a correction | 2 | 0 | |||||||||
| 23/130 - Genentech - GO44431 - CT1666 | GO44431 A phase I, open label, multicenter, dose escalation study evaluating the safety, pharmacokinetics, and activity of RO7566802 as a single agent and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors GO44431 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A phase I, open label, multicenter, dose escalation study evaluating the safety, pharmacokinetics, and activity of RO7566802 as a single agent and in combination with Atezolizumab in patients with locally advanced or metastatic solid tumors | PPD Australia Pty Ltd | Phase I | PCCTU EDD | Yes | 1/11/2023 | 26/09/2023 | Ben Tran | GO44431 | GO44431 | Click here | Report a correction | 12 | 1 | ||||||||||
| 23/171 - Gilead - GS-US-521-6317 - CT1689 | A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti�PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors GS-US-521-6317 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Study to Evaluate the Safety and Tolerability of GS-9911 as Monotherapy and in Combination With an Anti�PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors | Gilead Sciences Pty Ltd | Phase I | PCCTU EDD | Yes | 1/11/2023 | 31/10/2023 | Jayesh Desai | PCCTU EDD Team | GS-US-521-6317 | Click here | Report a correction | 10 | 1 | ||||||||||
| 23/49 - Regeneron Pharmaceuticals, Inc - CMP-001-009 - CT1614 | CMP-001-009 A multicenter, open-label, phase 2 study of intratumoral Vidutolimod (CMP-001) in combination with intravenous Cemiplimab in subjects with selected types of advanced or metastatic cancer. CMP-001-009 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A multicenter, open-label, phase 2 study of intratumoral Vidutolimod (CMP-001) in combination with intravenous Cemiplimab in subjects with selected types of advanced or metastatic cancer. | IQVIA | Phase II | Yes | 4/10/2023 | 24/10/2023 | Annette Lim | PCCTU MoncC Team | CMP-001-009 | CMP-001-009 | Click here | Report a correction | 8 | 1 | ||||||||||
| AstraZeneca - D8470C00001 - CYCAD-1 - CT1686 | CYAD-1 A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors. D8470C00001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants with Selected Advanced or Metastatic Solid Tumors. | AstraZeneca | Phase I/IIa | PCCTU Breast | Yes | 4/12/2023 | 22/11/2023 | Stephen Luen | PCCTU Breast Team | CYAD-1 | D8470C00001 | Report a correction | 10 | 0 | ||||||||||
| No CTA Finance - PMCC sponsored - DISCERN - NC | Comprehensive and deep profiling in cutaneous squamous cell carcinomas to unravel treatment efficacy in immunotherapy treated patients | PCCTU | Head & Neck | Cutaneous SCC | Cutaneous SCC | Comprehensive and deep profiling in cutaneous squamous cell carcinomas to unravel treatment efficacy in immunotherapy treated patients | PMCC Sponsored | N/A | Yes | 23/05/2023 | 23/05/2023 | Annette Lim | Click here | Report a correction | 10 | 4 | |||||||||||||
| Nuvation Bio - NUV-868-01 - CT1586 | Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors NUV-868-01 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Novotech | Phase I/II | PCCTU MoncA | Yes | 15/08/2023 | 15/08/2023 | Arun Azad | PCCTU MoncA Team | Phase 1/2 Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | NUV-868-01 | Click here | Report a correction | 8 | 1 | |||||||||
| Celgene BMS - IM043004 - CT1639 | IM043004 A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors IM043004 | Peninsula Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Open-label, Multicenter Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors | Celgene Pty Limited, a Bristol Myers Squibb company | Phase I | Yes | 13/10/2023 | Jacquelyn Thomson | IM043004 | IM043004 | Click here | Report a correction | 3 | 0 | ||||||||||||
| BMS - CA052002 - CT1620 | A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors CA052002 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors | Bristol Myers Squibb | Phase I/II | Yes | 28/08/2023 | 28/08/2023 | Melissa Moore | Susmit Bhowmik | A Phase 1/2 Study of BMS-986340 with and without Nivolumab or Docetaxel in Solid Tumors | CA052002 | Click here | Report a correction | 0 | |||||||||||
| Pfizer - C3651003 - PROACC-1 - CT1534 | PROACC-1 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab In Patients with Cancer, Cachexia, and Elevated Concentrations of Gdf-15, Followed by an Optional Open-Label Treatment Period C3651003 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab In Patients with Cancer, Cachexia, and Elevated Concentrations of Gdf-15, Followed by an Optional Open-Label Treatment Period | Pfizer Australia Pty Ltd | Phase II | Yes | 21/06/2023 | 21/06/2023 | Melissa Moore | Eleanor Cropp | PROACC-1 | C3651003 | Click here | Report a correction | 0 | |||||||||||
| PMCC sponsored - 20/044 - IMPARP-HRD - VC007 | IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects 20/044, VC007 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects | PMCC Sponsored | Phase II | Yes | 5/07/2022 | 5/07/2022 | Genni Newnham | Susmit Bhowmik | IMPARP-HRD | 20/044, VC007 | Click here | Report a correction | 0 | |||||||||||
| Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 | cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788 | St Vincent's Hospital - Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. | ICON Clinical Research | Phase III | Yes | 31/10/2019 | 31/10/2019 | Christopher Hart | Yijia Chen | cPOST | R2810-ONC-1788 | Click here | Report a correction | 0 | |||||||||||
| RMC-6291-001 - Allucent - CT1678 | Allucent Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors RMC-6291-001 | SWH | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors | Pharm-Olam International Pty Ltd | Phase Ib/II | Yes | 5/12/2023 | 26/10/2023 | Theresa Hayes | Allucent | RMC-6291-001 | Click here | Report a correction | 5 | 0 | |||||||||||
| 20/044 - IMPARP-HRD - VC007 | IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects 20/044, VC007 | Western Health | Head & Neck | Solid Tumour | Solid Tumour | An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination with Tislelizumab in Patients With Advanced Tumours with Homologous Recombination Repair Defects | Peter MacCallum Cancer Centre | Phase II | Yes | 29/05/2023 | 29/05/2023 | Keri-Lee Geneser | IMPARP-HRD | 20/044, VC007 | Click here | Report a correction | 15 | 1 | |||||||||||
| Aulos Bioscience, Inc - CP-AU-007-01 - CT1542 | CT1542 A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer CP-AU-007-01 | Western Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer | PPD | Phase I/II | Yes | 26/10/2023 | PHASE 1 TRIAL METASTATIC/Advanced patients | Catherine Oakman | CT1542 | CP-AU-007-01 | Click here | Report a correction | 1 | 0 | |||||||||||
| Pfizer - C3651003 - PROACC-1 - CT1534 | PROACC-1 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab In Patients with Cancer, Cachexia, and Elevated Concentrations of Gdf-15, Followed by an Optional Open-Label Treatment Period C3651003 | Western Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab In Patients with Cancer, Cachexia, and Elevated Concentrations of Gdf-15, Followed by an Optional Open-Label Treatment Period | Pfizer Australia Pty Ltd | Phase II | No | 11/04/2023 | 17/11/2023 | 5/04/2023 | Ruwani Mendis | PROACC-1 | C3651003 | Click here | Report a correction | 3 | 3 | ||||||||||
| PharmaSols - MT-5111_001 - CT1464 | 5111_001 A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors MT-5111_001 | Western Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors | Phase Ib | Team A | No | 11/03/2022 | 31/03/2023 | 7/03/2022 | Stage: Metastatic Breast Cancer Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort | Catherine Oakman | Lisa Magee | 5111_001 | MT-5111_001 | Click here | Report a correction | 5 | 0 | ||||||||
| Study Details | Site | Indication | Sub Therapeutic Area | Molecular Target | Phase | PI |
Head & Neck – Upcoming Studies
| cta_upcoming | s_external_protocol_id | Study Details | Site | Indication | Indication2 | Therapeutic Area2 | Molecular Target | Sub Therapeutic Area | Sub Therapeutic Area 2 | s_molecular_targets | s_recruitment_criteria | Sponsor | Phase | Team | Open to Accrual | Open to Accrual Date | Close to Accrual Date (String) | Completely Closed Date (String) | Site Initiation Visit Date (String) | Inclusion and Exclusion Criteria 2 | Notes | PI | Study Coordinator | s_nick | s_other_id | Inclusion and Exclusion Criteria url | Email CTA | Site Target | cta_enrolment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upcoming | No CTA Finance - Eli Lilly - J2G-MC-JZJB - LIBRETTO-531 - CT1176 | LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | Alfred - Medical Oncology | Head & Neck | Thyroid | Thyroid | A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer | Phase II | Yes | TK inhibitor. Worldwide shorage of Vandertanib. | Duncan Topliss | LIBRETTO-531 | J2G-MC-JZJB | https://classic.clinicaltrials.gov/ct2/show/NCT04211337?term=J2G-MC-JZJB&draw=2&rank=1#eligibility | Report a correction | 0 | |||||||||||||
| Upcoming | Tigermed - AMT-253-01 - AMT253-01 - CT1679 | AMT253-01 First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT-253-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | First-in-Human, Phase 1 Study of AMT-253, an Anti MUC18 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors | Multitude Therapeutics | Phase I | Yes | Andrew Haydon | AMT253-01 | AMT-253-01 | https://classic.clinicaltrials.gov/ct2/show/NCT05906862?term=AMT-253-01&draw=2&rank=1 | Report a correction | 5 | 0 | ||||||||||||
| Upcoming | UPCOMING - Actym Therapeutics - ACTM-838-01 - ACTM83801 - CT | ACTM83801 A Phase 1a/1b Open-label, Dose-escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors ACTM-838-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1a/1b Open-label, Dose-escalation and Expansion Study of ACTM-838 as a Single Agent in Patients with Advanced Solid Tumors | Novotech | Phase I | Yes | Andrew Haydon | ACTM83801 | ACTM-838-01 | Report a correction | 5 | 0 | |||||||||||||
| Upcoming | UPCOMING - GSK - P221530 - 221530 - CT | P221530 A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma 221530 | Alfred - Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | GlaxoSmithKline (GSK) | Phase III | Yes | Andrew Haydon | P221530 | 221530 | Report a correction | 5 | 0 | |||||||||||||
| Upcoming | UPCOMING - Incyte - INCB161734-101 - CT1680 | INCB161734-101 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734-101 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | IQVIA | Phase I | Yes | Ben Markman | INCB161734-101 | INCB161734-101 | Report a correction | 6 | 0 | |||||||||||||
| Upcoming | UPCOMING - MSD - MK-1200-002 - CT | MK-1200 for Advanced Solid Tumors A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors MK-1200-002 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors | Phase I/II | Yes | Sanjeev Gill | MK-1200 for Advanced Solid Tumors | MK-1200-002 | Report a correction | 0 | |||||||||||||||
| Upcoming | UPCOMING - PharmAbcine - MarkV-01 - KEYNOTE-E80 - CT | KEYNOTE-E80 A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors MarkV-01 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined with Pembrolizumab, in Patients with Advanced or Metastatic Solid Tumors | Novotech | Phase Ib | Yes | Mark Voskoboynik | KEYNOTE-E80 | MarkV-01 | https://classic.clinicaltrials.gov/ct2/show/NCT05957081?term=MarkV-01&recrs=ab&draw=2&rank=1 | Report a correction | 5 | 0 | ||||||||||||
| Upcoming | UPCOMING - Servier - CL195035001 - CT | CL195035001 A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP CL195035001 | Alfred - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP | Servier | Phase I | Yes | Malaka Ameratunga | CL195035001 | CL195035001 | Report a correction | 0 | ||||||||||||||
| Upcoming | Eisai Co - E7080-G000-303 - SELECT | The Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | Thyroid | The Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer | Eisai Co., Ltd. | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT01321554?term=NCT01321554&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Eli Lilly - J2G-MC-JZJB - LIBRETTO-531 - CT1176 | LIBRETTO-531 LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | Thyroid | LIBRETTO-531 A mulitcentre, randomised, open-label, phase 3 trial comparing LOXO-292 to physicians choice of Cabozantinib or Vandertanib in patients with progressive, advanced, kinase inhibitor naive, RET-mutant medullary thyroid cancer J2G-MC-JZJB | Eli Lilly | Phase III | Yes | TK inhibitor. Worldwide shorage of Vandertanib. | LIBRETTO-531 | https://classic.clinicaltrials.gov/ct2/show/NCT04211337?term=NCT04211337&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Exelixis - XL184-311 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | Thyroid | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy | Exelixis, Inc. | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03690388?term=NCT03690388&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Roche - CO42865 - AcceleRET-MTC | A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer. | Alfred Health - Endocrinology Department | Head & Neck | Thyroid | Thyroid | A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer. | F. Hoffmann-La Roche Ltd | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04760288?term=NCT04760288&draw=1&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Lawson Health - R-11-605 - SABR-COMET | SABR-COMET Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial R-11-605 | Alfred Health - Radiation Oncology Department | Head & Neck | Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trial | Lawson Health Research Institute | Phase II | Yes | SABR-COMET | R-11-605 | https://classic.clinicaltrials.gov/ct2/show/NCT01446744?term=NCT01446744&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | TROG - TROG 08.09 - 2009/039 - RTN2 | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (Other IDs: TROG 08.09, 2009/039, ANZMTG 01.09) | Alfred Health - Radiation Oncology Department | Head & Neck | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (Other IDs: TROG 08.09, 2009/039, ANZMTG 01.09) | TROG | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT00975520?term=NCT00975520&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||||
| Upcoming | Maverick Therapeutics - CP-MVC-101-01 - COBRA | COBRA A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer CP-MVC-101-01 | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer | Maverick Therapeutics | Phase I/II | Yes | COBRA | CP-MVC-101-01 | https://clinicaltrials.gov/ct2/show/NCT04844073?term=NCT04844073&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | No CTA Finance - Abbvie - M16-438 | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | AbbVie | Phase I | Yes | https://clinicaltrials.gov/ct2/show/record/NCT03234712?term=NCT03234712&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Akeso - AK117-101 | A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Multicenter, Open Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 in Subjects With Relapsed/Refractory Advanced or Metastatic Solid Tumors or Lymphomas | Akesobio Australia Pty Ltd | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04349969?term=NCT04349969&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Akesobio Australia Pty Ltd - AK104-101 - CT934 | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors | Akesobio Australia Pty Ltd | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03261011?term=NCT03261011&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Antengene - ATG-017-001 - ERASER | ERASER A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies | Antengene (AUS) PTY. LTD | Phase I | Yes | ERASER | https://clinicaltrials.gov/ct2/show/NCT04305249?term=NCT04305249&draw=2&rank=1 | Report a correction | 0 | |||||||||||||||
| Upcoming | No CTA Finance - Antengene - ATG-101-001 - PROBE - CT1471 | PROBE A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas ATG-101-001 | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas | Phase I | Yes | PROBE | ATG-101-001 | https://clinicaltrials.gov/ct2/show/NCT04986865?term=NCT04986865&draw=2&rank=1 | Report a correction | 0 | |||||||||||||||
| Upcoming | No CTA Finance - Arcus Biosciences - AB154CSP0001 | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Arcus Biosciences Australia Pty Ltd. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03628677?term=NCT03628677&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - AstraZeneca - D7310C00001 - Interlink-1 - CT1284 | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor | Austin Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor | AstraZeneca | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT04590963?term=NCT04590963&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Aulos Bioscience, Inc - CP-AU-007-01 - CT1542 | CT1542 A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer CP-AU-007-01 | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer | Aulos Bioscience, Inc | Phase I/II | Yes | Binds IL-2. | Andrew Weickhardt | CCTC Team 5 | CT1542 | CP-AU-007-01 | https://clinicaltrials.gov/ct2/show/NCT05267626?term=NCT05267626&draw=2&rank=1 | Report a correction | 1 | 0 | ||||||||||
| Upcoming | No CTA Finance - BeiGene - BGB-A317-3111 | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - BeiGene - ICP-CL-00303 | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04565275?term=NCT04565275&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - BMS - CA031-002 - TIM-3 | A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors | Bristol-Myers Squibb (BMS) | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03446040?term=NCT03446040&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - CStone - CS3005-101 | A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase I, Multi-center, Open-label, Dose Escalation Study of CS3005 in Subjects With Advanced Solid Tumors | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04233060?term=NCT04233060&draw=2&rank=1 | Report a correction | 0 | |||||||||||||||||
| Upcoming | No CTA Finance - Exelixis - XL184-401 - EXAMINER - CT720 | A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients | Austin Health | Head & Neck | Thyroid | Thyroid | A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients | Exelixis, Inc. | Phase IV | Yes | https://clinicaltrials.gov/ct2/show/NCT01896479?term=NCT01896479&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Five Prime Therapeutics - FPT155-001 - CT1051 | A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors | Five Prime Therapeutics, Inc. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04074759?term=NCT04074759&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Gilead - GS-US-548-5916 - CT1537 | ELEVATE HNSCC A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma GS-US-548-5916 | Austin Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma | Gilead | Phase II | Yes | Hui Gan | ELEVATE HNSCC | GS-US-548-5916 | https://classic.clinicaltrials.gov/ct2/show/NCT04854499?term=GS-US-548-5916&draw=2&rank=1#eligibility | Report a correction | 0 | |||||||||||||
| Upcoming | No CTA Finance - GSK - 209227 - INDUCE-4 - CT1255 | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Austin Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized, Double-Blind, Adaptive, Phase II/III Study of GSK3359609 in Combination With Pembrolizumab and 5FU-Platinum Chemotherapy Versus Placebo in Combination With Pembrolizumab Plus 5FU-Platinum Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | GlaxoSmithKline (GSK) | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT04428333?term=NCT04428333&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - GSK - 209229 - INDUCE 3 - CT1170 | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Austin Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | GlaxoSmithKline (GSK) | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT04128696?term=NCT04128696&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - GSK - GSK204691 - INDUCE-1 | A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors | GlaxoSmithKline (GSK) | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02723955?term=NCT02723955&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Harbour Biomed - 4003.1 - CT1167 | A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects With Advanced Solid Tumors | Harbour BioMed (Guangzhou) Co. Ltd | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04135261?term=NCT04135261&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Ignyta - RXDX-101-02 - STARTRK-2 | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Ignyta, Inc. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02568267?term=NCT02568267&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - MacroGenics - CP-MGD009-01 | Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms | Macrogenics Inc. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02628535?term=NCT02628535&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Merck - MK3475-048 - KEYNOTE-048 - CT755 | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Austin Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Merck | Phase III | Yes | Report a correction | 0 | |||||||||||||||||
| Upcoming | No CTA Finance - Novartis - CLAG525X2101C - LAG525 | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Austin Health | Head & Neck | Bladder, Cutaneous SCC, Prostate, Renal Cell (Kidney), Solid Tumour | Solid Tumour | A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies | Novartis Pharmaceuticals Australia Pty Limited | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02460224?term=NCT02460224&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Pfizer - B9991004 - JAVELIN Medley | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | Austin Health | Head & Neck | A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies | Pfizer Australia Pty Ltd | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02554812?term=NCT02554812&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||||
| Upcoming | No CTA Finance - Pfizer - B9991016 - JAVELIN HEAD AND NECK 100 | A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck | Austin Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck | Pfizer | Phase III | Yes | https://clinicaltrials.gov/ct2/show/NCT02952586?term=NCT02952586&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - RAPT Therapeutics - FLX475-02 | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer | Austin Health | Head & Neck | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer | RAPT Therapeutics, Inc. | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03674567?term=NCT03674567&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||||
| Upcoming | No CTA Finance - Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 | cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788 | Austin Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. | Regeneron Pharmaceuticals | Phase III | Yes | Anti-PD-1 monoclonal antibody. | Hui Gan | cPOST | R2810-ONC-1788 | https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility | Report a correction | 0 | ||||||||||||
| Upcoming | No CTA Finance -Incyte - INCB99280-112 | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors | Incyte Corporation | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04242199?term=NCT04242199&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | PMCC sponsored - 20/044 - IMPARP-HRD - VC007 | IMPARP-HRD An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects 20/044, VC007 | Austin Health | Head & Neck | Solid Tumour | Solid Tumour | An Open Label, Signal Seeking, Translational, Phase II Trial of Pamiparib in Combination With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects | PMCC Sponsored | Phase II | Yes | IMPARP-HRD | 20/044, VC007 | https://clinicaltrials.gov/ct2/show/NCT04985721?term=NCT04985721&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | UPCOMING - Australian Genomic Cancer Medicine Centre - ML43743 - MoST-TAP | MoST-TAP A single arm, open-label, phase II signal-seeking trial of tiragolumab and atezolizumab in patients with advanced solid tumours ML43743 | Bendigo | Head & Neck | Solid Tumour | Solid Tumour | A single arm, open-label, phase II signal-seeking trial of tiragolumab and atezolizumab in patients with advanced solid tumours | The George Institute | Phase II | Yes | Sam Harris | MoST-TAP | ML43743 | https://classic.clinicaltrials.gov/ct2/show/NCT06003621?term=MoST-TAP&draw=2&rank=1#eligibility | Report a correction | 0 | |||||||||||||
| Upcoming | UPCOMING - Bendigo Sponsored - OPTION - NC | OPTION OligoProgressive Treatment for ImmunOtherapy patieNts (OPTION) OPTION | Bendigo | Head & Neck | OligoProgressive Treatment for ImmunOtherapy patieNts (OPTION) | Bendigo Health | N/A | Yes | Sam Harris | OPTION | OPTION | Report a correction | 33 | 0 | |||||||||||||||
| Upcoming | UPCOMING - Servier - CL195035001 - CT | CL195035001 A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP CL195035001 | Bendigo | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP | Servier | Phase I | Yes | CL195035001 | CL195035001 | Report a correction | 0 | |||||||||||||||
| Upcoming | Adlai Nortye Biopharma - AN2025H0301 - BURAN | The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Border Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Adlai Nortye Biopharma Co. | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04338399?term=NCT04338399&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Akesobio - AK105-101 | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors AK105-101 | Border Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors | Akesobio Australia Pty Ltd | Phase I | Yes | AK105-101 | https://classic.clinicaltrials.gov/ct2/show/NCT03352531?term=NCT03352531&draw=2&rank=1 | Report a correction | 0 | |||||||||||||||
| Upcoming | Arcus Biosciences - AB154CSP0001 | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Border Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies | Arcus Biosciences Australia Pty Ltd. | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03628677?term=NCT03628677&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | CStone Pharmaceuticals - CS1003-101 - C-Stone | C-Stone A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors CS1003-101 | Border Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors | CStone Pharmaceuticals | Phase I | Yes | C-Stone | CS1003-101 | https://classic.clinicaltrials.gov/ct2/show/NCT03475251?term=NCT03475251&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Genentech - GO43712 | A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors GO43712 | Border Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase Ib, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors | Genentech | Phase I | Yes | GO43712 | https://classic.clinicaltrials.gov/ct2/show/NCT05487235?term=NCT05487235&draw=2&rank=1 | Report a correction | 0 | |||||||||||||||
| Upcoming | Ignyta - RXDX-101-02 - STARTRK-2 | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Border Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements | Ignyta, Inc. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02568267?term=NCT02568267&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Immutep S.A.S. - TACTI-003 - IMP321-P022 - KEYNOTE- PNC-34 | TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Border Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | TACTI-003 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Randomized, Phase II Trial to Investigate a Soluble LAG-3 Fusion Protein, Eftilagimod Alpha (Efti; IMP321) in Combination With Pembrolizumab (PD-1 Antagonist) for First Line Treatment of Subjects With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Immutep S.A.S. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04811027?term=NCT04811027&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | No CTA Finance - Regeneron Pharmaceuticals - R2810-ONC-1788 - cPOST - CT1126 | cPOST A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. R2810-ONC-1788 | Border Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | A randomized, placebo-controlled, double-blind study of adjuvant cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. | Regeneron Pharmaceuticals | Phase III | Yes | Anti-PD-1 monoclonal antibody. | Richard Eek | cPOST | R2810-ONC-1788 | https://classic.clinicaltrials.gov/ct2/show/NCT03969004?term=NCT03969004&draw=2&rank=1#eligibility | Report a correction | 0 | ||||||||||||
| Upcoming | Regeneron Pharmaceuticals Inc - R2810-ONC-1540 - Regeneron 2 - CT823 | A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Border Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma | Regeneron Pharmaceuticals | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02760498?term=NCT02760498&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | UPCOMING - DynamiCure Biotechnology - DCBY02-101 - CT | DCBY02-101 A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors DCBY02-101 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Novotech | Phase I | Yes | Gary Richardson | DCBY02-101 | DCBY02-101 | https://classic.clinicaltrials.gov/ct2/show/NCT05496595?term=DCBY02-101&draw=2&rank=1#eligibility | Report a correction | 5 | 0 | ||||||||||||
| Upcoming | UPCOMING - Exelixis - XL092-002 - STELLAR-002 - CT | STELLAR-002 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors XL092-002 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | ICON plc | Phase Ib | Yes | Gary Richardson | STELLAR-002 | XL092-002 | https://classic.clinicaltrials.gov/ct2/show/NCT05176483?term=XL092-002&draw=2&rank=1 | Report a correction | 5 | 0 | ||||||||||||
| Upcoming | UPCOMING - Novotech - AMT-676-01 - CT | AMT-676-01 First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors AMT-676-01 | Cabrini | Head & Neck | Solid Tumour | Solid Tumour | First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors | Phase I | Yes | AMT-676-01 | AMT-676-01 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Beigene - BGB-290-AU-102 | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Eastern | Head & Neck | Solid Tumour | Solid Tumour | Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT03744468?term=NCT03744468&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Checkpoint Therapeutics - CK-301-101 | CK-301-101 A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers CK-301-101 | Eastern | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers | Checkpoint Therapeutics, Inc. | Phase I | Yes | CK-301-101 | CK-301-101 | https://classic.clinicaltrials.gov/ct2/show/NCT03212404?term=NCT03212404&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | UPCOMING - MSD - MK-1200-002 - CT | MK-1200 for Advanced Solid Tumors A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors MK-1200-002 | Epworth | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors | Phase I/II | Yes | Sumitra Ananda | MK-1200 for Advanced Solid Tumors | MK-1200-002 | Report a correction | 0 | |||||||||||||||
| Upcoming | UPCOMING - GSK - P221530 - 221530 - CT | P221530 A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma 221530 | Grampians Health | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | GlaxoSmithKline (GSK) | Phase III | Yes | P221530 | 221530 | Report a correction | 0 | |||||||||||||||
| Upcoming | UPCOMING - PMCC Sponsored - Cancer Statewide_26072023 - NC | Cancer Statewide A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia Cancer Statewide_26072023 | LRH | Head & Neck | Other | Other | A hybrid type III effectiveness and implementation trial of complex genomic profiling in patients with advanced cancer using three models of care in metropolitan and regional oncology centres in Victoria, Australia | PMCC Sponsored | N/A | Yes | Sachin Joshi | Cancer Statewide | Cancer Statewide_26072023 | Report a correction | 40 | 0 | |||||||||||||
| Upcoming | BeiGene - BGB-A317-3111 | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Monash Health - Haematology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Akesobio - AK112-01 | AK112-01 A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumors AK112-01 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects with Advanced Solid Tumors | Akesobio | Phase I | Yes | AK112-01 | AK112-01 | https://classic.clinicaltrials.gov/ct2/show/NCT04047290?term=NCT04047290&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | AMGEN - 20180144 - AMG144 | AMG144 A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors 20180144 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors | Amgen | Phase I | Yes | AMG144 | 20180144 | https://classic.clinicaltrials.gov/ct2/show/NCT04362748?term=NCT04362748&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Ascendis Pharma Oncology Division - TCTLR-101 | Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Ascendis Pharma Oncology Division A/S | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04799054?term=NCT04799054&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Aulos Bioscience, Inc - CP-AU-007-01 - CT1542 | CT1542 A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer CP-AU-007-01 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R? Binding, in Patients with Unresectable Locally Advanced or Metastatic Cancer | Aulos Bioscience, Inc | Phase I/II | Yes | Binds IL-2. | Sophia Frentzas | A M | CT1542 | CP-AU-007-01 | https://clinicaltrials.gov/ct2/show/NCT05267626?term=NCT05267626&draw=2&rank=1 | Report a correction | 0 | |||||||||||
| Upcoming | BeiGene - BGB-900-105 - TIGIT | TIGIT Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors BGB-900-105 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase Ib | Yes | TIGIT | BGB-900-105 | https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | BeiGene - BGB-A317-3111-10188-101 | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors | Beigene | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04282018?term=NCT04282018&draw=1&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | BeiGene - BGB-A317-A445-101 - OX40 | Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04215978?term=NCT04215978&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | BeiGene - ICP-CL-00303 | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Multi-center Open-label, Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-192 in Patients With Advanced Solid Tumors and FGFR Gene Alterations | Beigene | Phase I/II | Yes | https://clinicaltrials.gov/ct2/show/NCT04565275?term=NCT04565275&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | BMS - CA209-651 - CheckMate 651 | An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Monash Health - Oncology Department | Head & Neck | Cutaneous SCC | Cutaneous SCC | An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Bristol-Myers Squibb (BMS) | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT02741570?term=NCT02741570&draw=1&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Corvus Pharmaceuticals - CPI-006-001 | CPI-006-001 A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers CPI-006-001 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers | Corvus Pharmaceuticals, Inc | Phase I | Yes | CPI-006-001 | CPI-006-001 | https://classic.clinicaltrials.gov/ct2/show/NCT03454451?term=NCT03454451&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Epimab - EMB02X101 | A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase I/II Trial of EMB-02, a Bi-specific Antibody Against PD-1 and LAG-3, in Patients With Advanced Solid Tumors | Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04618393?term=NCT04618393&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Haihe Biopharma - CYH33-G102 | Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | Haihe Biopharma Co., Ltd. | Phase Ib | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04586335?term=NCT04586335&draw=1&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | LaNova - LM302-01-201 | LANOVA A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors LM302-01-201 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-302 in Combination with Toripalimab in Patients with Advanced Solid Tumors | LaNova Australia | Phase I/II | Yes | LANOVA | LM302-01-201 | https://classic.clinicaltrials.gov/ct2/show/NCT05188664?term=NCT05188664&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | MacroGenics - CP-MGA271-06 | A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Monash Health - Oncology Department | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 2 Open-Label Trial to Evaluate Enoblituzumab in Combination With Retifanlimab or Tebotelimab in the First-Line Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Macrogenics Inc. | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04634825?term=NCT04634825&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Maverick Therapeutics - CP-MVC-101-01 - COBRA | COBRA A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer CP-MVC-101-01 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 Conditional Bispecific Redirected Activation Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer | Maverick Therapeutics | Phase I/II | Yes | COBRA | CP-MVC-101-01 | https://clinicaltrials.gov/ct2/show/NCT04844073?term=NCT04844073&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Merck - MK-1084 - MK-1084-001 | 1084-001 A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors MK-1084-001 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors | Merck | Phase I | Yes | 1084-001 | MK-1084-001 | https://classic.clinicaltrials.gov/ct2/show/NCT05067283?term=NCT05067283&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Merck - MK-145-002 | A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy | Monash Health - Oncology Department | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy | Merck | Phase II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04220866?term=NCT04220866&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Merck - MK-7339-007 - KEYLYNK-007 | KEYLYNK-007 A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer MK-7339-007 | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer | Merck | Phase II | Yes | KEYLYNK-007 | MK-7339-007 | https://classic.clinicaltrials.gov/ct2/show/NCT04123366?term=NCT04123366&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Merck - MK-7902-009 - LEAP-009 | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) | Monash Health - Oncology Department | Head & Neck | Mucosal | Mucosal | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) | Merck | Phase II | Yes | Muhammad Alamgeer | https://classic.clinicaltrials.gov/ct2/show/NCT04428151?term=NCT04428151&draw=2&rank=1 | Report a correction | 0 | |||||||||||||||
| Upcoming | Senz Oncology - EOHC-1001-01 | An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer. | Monash Health - Oncology Department | Head & Neck | Other | Other | An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer. | Senz Oncology | Phase I/II | Yes | Report a correction | 0 | |||||||||||||||||
| Upcoming | Takeda - TAK-280-1501 | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer | Takeda Oncology | Phase I/II | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT05220098?term=NCT05220098&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Vivace - VT3989-001 | Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene | Vivace Therapeutics, Inc | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04665206?term=NCT04665206&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | Wellmarker Bio - WMS1030-101 - WM-S1-030 | A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors | Monash Health - Oncology Department | Head & Neck | Solid Tumour | Solid Tumour | A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors | Wellmarker Bio | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT04801095?term=NCT04801095&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | UPCOMING - Abbvie - M23-385 - CT | M23-385 A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors M23-385 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors | Parexel | Phase I | PCCTU MoncC | Yes | Michael Michael | PCCTU MoncC Team | M23-385 | M23-385 | https://classic.clinicaltrials.gov/ct2/show/NCT05599984?term=M23-385&draw=2&rank=1#eligibility | Report a correction | 10 | 0 | ||||||||||
| Upcoming | UPCOMING - AstraZeneca - D9970C00001 - PRIMROSE - CT | PRIMROSE A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient D9970C00001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient | AstraZeneca | Phase I | PCCTU MoncB | Yes | Ben Solomon | PCCTU MoncB Team | PRIMROSE | D9970C00001 | Report a correction | 0 | ||||||||||||
| Upcoming | UPCOMING - Incyte - INCB161734-101 - CT1680 | INCB161734-101 A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734-101 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | IQVIA | Phase I | PCCTU EDD | Yes | Jayesh Desai | PCCTU EDD Team | INCB161734-101 | INCB161734-101 | Report a correction | 10 | 0 | |||||||||||
| Upcoming | UPCOMING - PPD - BLU-222-1101 - VELA - CT1563 | VELA A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors BLU-222-1101 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors | PPD Australia Pty Ltd | Phase I/II | PCCTU Gynae | Yes | George Au-Yeung | VELA | BLU-222-1101 | https://clinicaltrials.gov/ct2/show/NCT05252416?term=BLU-222-1101&draw=2&rank=1 | Report a correction | 8 | 0 | |||||||||||
| Upcoming | UPCOMING - Servier - CL1-95012-001 - CT1463 | CT1463 A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS CL1-95012-001 | PCCTU | Head & Neck | Solid Tumour | Solid Tumour | A FIRST IN HUMAN PHASE 1/2 OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF PRS-344/S095012 IN PATIENTS WITH SOLID TUMORS | Servier laboratories (AUST.) | Phase I/II | PCCTU Gynae | Yes | Linda Mileshkin | PCCTU Gynae Team | CT1463 | CL1-95012-001 | https://classic.clinicaltrials.gov/ct2/show/NCT05159388?term=CL1-95012-001&draw=2&rank=1 | Report a correction | 5 | 0 | ||||||||||
| Upcoming | TROG - 2009/039 - 01.09 - RTN2 | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck | PMCC - Cancer Surgery Department | Head & Neck | Other | Other | A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck | TROG | Phase III | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT00975520?term=NCT00975520&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | PMCC Sponsored - PMC67199 - PARLuNET | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC - Molecular Imaging Department | Head & Neck | Neuroendocrine, Pancreatic, Sarcoma | Sarcoma | Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor | PMCC Sponsored | Phase I | Yes | https://classic.clinicaltrials.gov/ct2/show/NCT05053854?term=NCT05053854&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||||
| Upcoming | PMCC Sponsored - U1111-1156-8748 - FSRT - EYE STUDY | Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma? | PMCC - Moorabbin / Radiation Oncology | Head & Neck | Can reduced dose radiotherapy delivered in standard fractionation improve the therapeutic index for stereotactic treatment of juxtapapillary choroidal melanoma? | PMCC Sponsored | Phase 0/I | Yes | Report a correction | 0 | |||||||||||||||||||
| Upcoming | BeiGene - BGB-900-105 - TIGIT | TIGIT Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors BGB-900-105 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors | Beigene | Phase Ib | Yes | TIGIT | BGB-900-105 | https://classic.clinicaltrials.gov/ct2/show/NCT04047862?term=NCT04047862&draw=2&rank=1 | Report a correction | 0 | ||||||||||||||
| Upcoming | Debiopharm International SA - DEBIO-1143 - TrilynX | TrilynX A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) DEBIO-1143 | St Vincent's Hospital - Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | Debiopharm International S.A | Phase III | Yes | TrilynX | DEBIO-1143 | https://classic.clinicaltrials.gov/ct2/show/NCT04459715?term=NCT04459715&draw=2&rank=1#eligibility | Report a correction | 0 | ||||||||||||||
| Upcoming | Janssen-Cilag - CR108661 - RAGNAR | RAGNAR A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations CR108661 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations | Janssen Cilag | Phase II | Yes | RAGNAR | CR108661 | https://classic.clinicaltrials.gov/ct2/show/NCT04083976?term=NCT04083976&draw=2&rank=1#eligibility | Report a correction | 0 | ||||||||||||||
| Upcoming | Merck - MK-3475-B10 - KEYNOTEB10 | KEYNOTEB10 A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. MK-3475-B10 | St Vincent's Hospital - Medical Oncology | Head & Neck | Cutaneous SCC | Cutaneous SCC | A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. | Merck | Phase IV | Yes | KEYNOTEB10 | MK-3475-B10 | https://classic.clinicaltrials.gov/ct2/show/NCT04489888?term=NCT04489888&draw=2&rank=1#eligibility | Report a correction | 0 | ||||||||||||||
| Upcoming | Molecular Templates - MT - 5111_001 | 5111_001 A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors MT-5111_001 | St Vincent's Hospital - Medical Oncology | Head & Neck | Solid Tumour | Solid Tumour | A Phase 1 Open-label, Multicenter Dose Escalation and Expansion Study of MT-5111 in Subjects With Previously Treated Advanced HER2-positive Solid Tumors | Molecular Templates Inc | Phase I/II | Yes | Tumour agnostic, HER2 altered Breast cancer expansion arm Must have HER2 expression on latest biopsy of a metastatic deposit Can be HER2 IHC2+ and non ISH-amplified Breast cancer cohort now in expansion Maximum tolerated dose reached in non-breast cohort | 5111_001 | MT-5111_001 | https://classic.clinicaltrials.gov/ct2/show/NCT04029922?term=NCT04029922&draw=2&rank=1#eligibility | Report a correction | 0 | |||||||||||||
| Upcoming | TROG 12.01 - HPV OROPHARYNX | HPV OROPHARYNX A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma TROG 12.01 | St Vincent's Hospital - Medical Oncology | Head & Neck | Other | Other | A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma | TROG | Phase III | Yes | HPV OROPHARYNX | TROG 12.01 | https://classic.clinicaltrials.gov/ct2/show/NCT01855451?term=NCT01855451&draw=2&rank=1#eligibility | Report a correction | 0 | ||||||||||||||
| Upcoming | UPCOMING - ImmVirX - CP-IVX001 | CP-IVX001 A phase 1 open-label, non-randomized, multi-cohort clinical study of intratumoral IVX037 as monotherapy or in combination with an immune checkpoint inhibitor in patients with advanced or metastatic solid tumors. CP-IVX001 | Western Health | Head & Neck | Solid Tumour | Solid Tumour | A phase 1 open-label, non-randomized, multi-cohort clinical study of intratumoral IVX037 as monotherapy or in combination with an immune checkpoint inhibitor in patients with advanced or metastatic solid tumors. | Novotech | Phase I | Yes | CP-IVX001 | CP-IVX001 | https://classic.clinicaltrials.gov/ct2/show/NCT05427487?term=CP-IVX001&draw=2&rank=1#eligibility | Report a correction | 0 | ||||||||||||||
| Study Details | Site | Indication | Molecular Target | Sub Therapeutic Area | Phase |